Seebri's inhalation capsules utilize glycopyrronium bromide, a member of the long-acting muscarinic receptor antagonist (LAMA) class. Engineered for sustained relief, this medication employs a significant mechanism of action that greatly impacts respiratory function for individuals with chronic obstructive pulmonary disease (COPD).
Glycopyrronium bromide is at the core of its effectiveness, acting as a selective antagonist at muscarinic receptors, particularly the M3 subtype. By inhibiting acetylcholine binding to these receptors, glycopyrronium curbs the parasympathetic tone responsible for bronchoconstriction and mucus production. This leads to airway dilation and reduced mucus, collectively improving respiratory function.
The distinct characteristic of glycopyrronium bromide is its lasting effect, indicating its long-acting nature. This extended impact ensures the bronchodilatory response persists, contributing to sustained symptom relief. Its mechanism aligns with that of tiotropium, another established bronchodilator, underscoring its efficacy in maintaining open airways.
Inhaled glycopyrronium bromide finds utility as both a standalone treatment and in fixed-dose combination therapies, accommodating various patient needs. By addressing the underlying causes of airway obstruction, the medication tackles both symptomatic relief and the disease's fundamental physiology.
Seebri inhalation capsules offer potential for those managing moderate to severe chronic obstructive pulmonary disease. It notably assists with conditions like emphysema, where airway obstruction triggers hallmark symptoms such as shortness of breath, coughing, and heightened mucus production. By alleviating these symptoms, Seebri empowers patients to regain respiratory control, thereby enhancing their quality of life.
Active principles: glycopyrronium bromide
Amount: 28 doses
Maker: Meiji Seika Pharma Co., Ltd., Tokyo, Japan
Indications: inducing a remission of symptoms caused by airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema).
Adults should inhale 1 capsule (50 mcg of glycopyrronium) a time, once a day, with using special inhaler (Seebri Breezhaler) at the same time every day. Never take the capsule orally; it should be used only for inhalation.
Contraindications: do not use for the following patients:
Take out the capsule from the aluminum package (blister package) immediately before using it.
Take care not to get this medicine into the eye. If conjunctival congestion, red eye due to corneal edema or eye pain occurs, see your ophthalmologist immediately.
If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.
